Calliditas Therapeutics Ab (CLTEF)

Calliditas Therapeutics Ab (CLTEF) — VMCI valuation read

Calliditas Therapeutics Ab sits at VMCI 32/100, with the Technology sector median at 50. That 18-point spread is the first thing to note on CLTEF: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on CLTEF are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on CLTEF: CLTEF trades at 14.0x earnings, 22% below the Technology median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Technology median (10.0%). The Risk read: net debt to EBITDA of 2.0x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

CLTEF fell 0.8% over the trailing 7 days, with a -1.0% read on a 30-day basis.